162 related articles for article (PubMed ID: 20861007)
1. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C.
Moucari R; Forestier N; Larrey D; Guyader D; Couzigou P; Benhamou Y; Voitot H; Vidaud M; Seiwert S; Bradford B; Zeuzem S; Marcellin P
Gut; 2010 Dec; 59(12):1694-8. PubMed ID: 20861007
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
Forestier N; Larrey D; Guyader D; Marcellin P; Rouzier R; Patat A; Smith P; Bradford W; Porter S; Blatt L; Seiwert SD; Zeuzem S
J Hepatol; 2011 Jun; 54(6):1130-6. PubMed ID: 21145848
[TBL] [Abstract][Full Text] [Related]
3. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.
Reiser M; Hinrichsen H; Benhamou Y; Reesink HW; Wedemeyer H; Avendano C; Riba N; Yong CL; Nehmiz G; Steinmann GG
Hepatology; 2005 Apr; 41(4):832-5. PubMed ID: 15732092
[TBL] [Abstract][Full Text] [Related]
4. Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir.
Le Pogam S; Yan JM; Chhabra M; Ilnicka M; Kang H; Kosaka A; Ali S; Chin DJ; Shulman NS; Smith P; Klumpp K; Nájera I
Antimicrob Agents Chemother; 2012 Nov; 56(11):5494-502. PubMed ID: 22869576
[TBL] [Abstract][Full Text] [Related]
5. Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution.
Lim SR; Qin X; Susser S; Nicholas JB; Lange C; Herrmann E; Hong J; Arfsten A; Hooi L; Bradford W; Nájera I; Smith P; Zeuzem S; Kossen K; Sarrazin C; Seiwert SD
Antimicrob Agents Chemother; 2012 Jan; 56(1):271-9. PubMed ID: 22064535
[TBL] [Abstract][Full Text] [Related]
6. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.
Vallet S; Viron F; Henquell C; Le Guillou-Guillemette H; Lagathu G; Abravanel F; Trimoulet P; Soussan P; Schvoerer E; Rosenberg A; Gouriou S; Colson P; Izopet J; Payan C;
Antivir Ther; 2011; 16(7):1093-102. PubMed ID: 22024525
[TBL] [Abstract][Full Text] [Related]
7. Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection.
Deutsch M; Papatheodoridis GV
Curr Opin Investig Drugs; 2010 Aug; 11(8):951-63. PubMed ID: 20721837
[TBL] [Abstract][Full Text] [Related]
8. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.
Silva MO; Treitel M; Graham DJ; Curry S; Frontera MJ; McMonagle P; Gupta S; Hughes E; Chase R; Lahser F; Barnard RJ; Howe AY; Howe JA
J Hepatol; 2013 Jul; 59(1):31-7. PubMed ID: 23454058
[TBL] [Abstract][Full Text] [Related]
9. Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.
Suzuki F; Suzuki Y; Akuta N; Sezaki H; Yatsuji H; Arase Y; Hirakawa M; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Iwasaki S; Kumada H
J Clin Virol; 2010 Jan; 47(1):76-8. PubMed ID: 19857995
[TBL] [Abstract][Full Text] [Related]
10. Boceprevir, an NS3 protease inhibitor of HCV.
Berman K; Kwo PY
Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
[TBL] [Abstract][Full Text] [Related]
11. Telaprevir: hope on the horizon, getting closer.
Weisberg IS; Jacobson IM
Clin Liver Dis; 2009 Aug; 13(3):441-52. PubMed ID: 19628160
[TBL] [Abstract][Full Text] [Related]
12. [Antiviral treatment of chronic hepatitis C].
Berger A
Med Monatsschr Pharm; 2012 Feb; 35(2):55-60. PubMed ID: 22400430
[TBL] [Abstract][Full Text] [Related]
13. Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus.
Nakamura H; Ogawa H; Kuroda T; Yamamoto M; Enomoto H; Kishima Y; Yoshida K; Ito H; Matsuda M; Noguchi S
Hepatogastroenterology; 2002; 49(47):1373-6. PubMed ID: 12239945
[TBL] [Abstract][Full Text] [Related]
14. A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.
Canini L; Chatterjee A; Guedj J; Lemenuel-Diot A; Brennan B; Smith PF; Perelson AS
Antivir Ther; 2015; 20(5):469-77. PubMed ID: 25321394
[TBL] [Abstract][Full Text] [Related]
15. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy.
Vicenti I; Rosi A; Saladini F; Meini G; Pippi F; Rossetti B; Sidella L; Di Giambenedetto S; Almi P; De Luca A; Caudai C; Zazzi M
J Antimicrob Chemother; 2012 Apr; 67(4):984-7. PubMed ID: 22258932
[TBL] [Abstract][Full Text] [Related]
16. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection.
Hsu CS; Liu CH; Liu CJ; Wang CC; Chen CL; Lai MY; Chen PJ; Chen DS; Kao JH
Am J Gastroenterol; 2009 Mar; 104(3):598-604. PubMed ID: 19262519
[TBL] [Abstract][Full Text] [Related]
17. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
Chu CM; Sheen IS; Liaw YF
Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
[TBL] [Abstract][Full Text] [Related]
18. A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients.
Lawitz EJ; Hill JM; Marbury T; Demicco MP; Delaney W; Yang J; Moorehead L; Mathias A; Mo H; McHutchison JG; Rodriguez-Torres M; Gordon SC
Antivir Ther; 2013; 18(3):311-9. PubMed ID: 23047118
[TBL] [Abstract][Full Text] [Related]
19. Insulin resistance, viral load and response to peginterferon and ribavirin in patients with chronic hepatitis C virus infection.
Dai CY; Huang JF; Hsieh MY; Chuang WL; Yu ML
Gut; 2010 Mar; 59(3):418. PubMed ID: 20207653
[No Abstract] [Full Text] [Related]
20. Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals.
Nguyen LT; Gray E; Dean J; Carr M; Connell J; De Gascun C; Nguyen LA; O'Leary A; Bergin C; Hall W; Norris S
Antivir Ther; 2015; 20(8):865-9. PubMed ID: 25920764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]